pulegone and Disease-Models--Animal

pulegone has been researched along with Disease-Models--Animal* in 2 studies

Other Studies

2 other study(ies) available for pulegone and Disease-Models--Animal

ArticleYear
(R)-(+)-pulegone suppresses allergic and inflammation responses on 2,4-dinitrochlorobenzene-induced atopic dermatitis in mice model.
    Journal of dermatological science, 2018, Volume: 91, Issue:3

    (R)-(+)-pulegone (PLG), a biotransformation of monoterpene ketones, is one of essential oils of Labiatae family. Although PLG was reported to have anti-inflammatory and anti-histamine effects, the therapeutic effects of PLG on atopic dermatitis (AD) have not been reported yet.. This study investigated the anti-AD effects and underlying mechanisms of PLG in AD-induced mice.. BALB/c male mice were challenged with 2, 4-dinitrochlorobenzene (DNCB, 1%) to induce AD. After 4 days of rest, PLG (0.1, 1 and 10 μM) were topically applied to dorsal skin for 2 weeks with secondary elicitation using 0.5% DNCB. Histological changes were identified by H&E staining and mast cells were evaluated by toluidine blue staining. Pro-inflammatory cytokines and serum IgE levels were analyzed by ELISA. Inflammatory mediators were measured by western blotting assay.. Topical treatment with PLG significantly suppressed skin thickness and scratching behavior compared with control group. Expression of nerve growth factor was also decreased by PLG treatment. PLG administration decreased serum IgE levels and the number of mast cells in mice model of DNCB-induced AD. The levels of IL-4, IFN-γ, IL-6, TNF-α and IL-1β in dorsal skin of PLG-treated group were lower than those in the control group. PLG inhibited the phosphorylation of MAPKs, as well as IκBα degradation and NF-κB activation.. PLG attenuated the symptoms of AD by suppressing cytokines production, the phosphorylation of MAPKs and the activation of NF-κB signaling. These data suggest that PLG may be an effective natural compound for the treatment of inflammatory skin diseases.

    Topics: Animals; Anti-Allergic Agents; Anti-Inflammatory Agents; Cyclohexane Monoterpenes; Cytokines; Dermatitis, Allergic Contact; Dermatitis, Atopic; Dinitrochlorobenzene; Disease Models, Animal; Immunoglobulin E; Inflammation Mediators; Male; Mice, Inbred BALB C; Mitogen-Activated Protein Kinases; Monoterpenes; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Proteolysis; Pruritus; Signal Transduction; Skin; Th1-Th2 Balance

2018
Mitigation of pennyroyal oil hepatotoxicity in the mouse.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2003, Volume: 10, Issue:10

    Pennyroyal oil ingestion has been associated with severe hepatotoxicity and death. The primary constituent, R-(+)-pulegone, is metabolized via hepatic cytochrome P450 to toxic intermediates. The purpose of this study was to assess the ability of the specific cytochrome P450 inhibitors disulfiram and cimetidine to mitigate hepatotoxicity in mice exposed to toxic levels of R-(+)-pulegone.. 20-g female BALB/c mice were pretreated with either 150 mg/kg of cimetidine intraperitoneal (IP), 100 mg/kg of disulfiram IP, or both. After one hour, mice were administered 300 mg/kg of pulegone IP and were killed 24 hours later. Data were analyzed using ANOVA. Post-hoc t-tests used Bonferroni correction.. There was a tendency for lower serum glutamate pyruvate transaminase in the disulfiram and cimetidine groups compared with the R-(+)-pulegone group. The differences were significant for both the cimetidine and the combined disulfram and cimetidine groups compared with the R-(+)-pulegone group. Pretreatment with the combination of disulfiram and cimetidine most effectively mitigated R-(+)-pulegone-induced hepatotoxicity.. Within the limitations of a pretreatment animal model, the combination of cimetidine and disulfiram significantly mitigates the effects of pennyroyal toxicity and does so more effectively than either agent alone. These data suggest that R-(+)-pulegone metabolism through CYP1A2 appears to be more important in the development of a hepatotoxic metabolite than does metabolism via CYP2E1.

    Topics: Animals; Case-Control Studies; Cimetidine; Cyclohexane Monoterpenes; Cyclohexanones; Disease Models, Animal; Disulfiram; Enzyme Inhibitors; Female; Hedeoma; Liver Diseases; Mentha pulegium; Mice; Mice, Inbred BALB C; Monoterpenes; Oils, Volatile

2003